Compare Amylx Pharmaceuticals Inc (AMLX) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs General Dynamics Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while General Dynamics Corporation trades at $375.2 (market cap $101.43B). The key difference: General Dynamics Corporation is far larger — about 51.2× Amylx Pharmaceuticals Inc's market cap, and General Dynamics Corporation pays a 1.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GD | |
|---|---|---|
Market Cap | $1.98B | $101.43B |
Sector | Health | Industrials |
52-Week High | $18.70 | $376.88 |
52-Week Low | $7.64 | $297.05 |
Enterprise Value | $1.70B | $107.61B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
General Dynamics (GD) trades at $375.06, up 0.12% today, near its 52-week high with strong technical momentum. The stock shows robust fundamentals, including consistent earnings beats, revenue growth to $52.55B in 2025, and healthy margins. Analyst sentiment is bullish, with a consensus price target of $395.83, supported by a backlog surge to $130.8B in Q1 2026 (Seeking Alpha, 2026-07-02).
Outlook remains positive due to defense spending tailwinds and submarine contract wins, but risks include execution delays and valuation concerns. The stock offers growth potential with a 5.6% upside to consensus target, though high RSI levels suggest near-term overbought conditions. Investors should weigh strong cash flow and dividend stability against geopolitical and supply chain uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
